ArticleTranslational psychiatry2025
Relationship between hippocampal volume and treatment response before and after escitalopram administration in patients with depression.
Article in Translational psychiatry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Reconciling the neurogenic hypothesis of depression with recent advances in adult hippocampal neurogenesis research in humans.Molecular psychiatry · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
The hippocampus plays a crucial role in memory formation and emotional regulation, and is closely related to the pathology of depression. Escitalopram, a selective serotonin reuptake inhibitor, promotes neurogenesis in the dentate gyrus of the hippocampus and alters its structure. This study examined the relationship between these escitalopram-induced structural changes and treatment response in 107 patients with moderate to severe depression, of whom 56 were female (52.3%), with a mean age of 41.5 years (range: 25-73 years). Follow-up data were available for 71 patients (66.4%). Changes in the volume and laterality of hippocampal subregions were compared before and after escitalopram treatment between Responders to escitalopram (n = 53) and Nonresponders (n = 54). The results indicated that Responders had a larger left hippocampal volume (β = 189.3, 95% CI [71.4, 307.2], Cohen's f² ≈ 0.094) and greater leftward laterality (β = 0.012, 95% CI [2.2 × 10⁻⁴, 0.024], Cohen's f² ≈ 0.04) than Nonresponders at baseline. Additionally, the right hippocampus and right hippocampal head exhibited increased volume (β = 80.6, 95% CI [28.5, 132.8], Cohen's f² ≈ 0.005; β = 50.4, 95% CI [22.2, 78.5], Cohen's f² ≈ 0.006) and altered laterality (β = -0.011, 95% CI [-0.022, -4.1 × 10⁻⁴], Cohen's f² ≈ 0.003; β = -3.3 × 10⁻⁴, 95% CI [-5.7 × 10⁻⁴, -8.3 × 10⁻⁵], Cohen's f² ≈ 0.006) in response to escitalopram in Responders compared to Nonresponders. Furthermore, the volume changes in the right hippocampus and right hippocampal head correlated with core depressive symptoms. It is suggested that these volume changes play an important role in the improvement of core symptoms of depression by escitalopram treatment. These findings can help to reveal the mechanisms of action of selective serotonin reuptake inhibitors and have the potential to facilitate the early identification of patients who will respond to treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.